JAKPOT T1D: Abrocitinib and ritlecitinib in new-onset T1D
What this study tests
TrialNet/NIDDK phase-2 trial comparing two selective oral JAK-pathway drugs - abrocitinib and ritlecitinib - with placebo for preservation of C-peptide in newly diagnosed T1D.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-09-02.
Most recent recorded citation date: 2026-05-29. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Ages 12–35, diagnosed within 100 days of baseline, with at least one islet autoantibody, stimulated C-peptide at least 0.2 nmol/L, HbA1c at most 10% and weight at least 35 kg. Additional infection, vaccination and safety criteria apply. Recruitment is closed. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted when checked 16 September 2026. Active, not recruiting; estimated enrollment 78. The 2 September update moves estimated primary completion to 30 October 2026 and full completion to 30 October 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States, Canada, Australia. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Australian sites in the registry
- Royal North Shore Hospital, Saint Leonards, New South Wales — Site status not reported
- Queensland Children's Hospital, South Brisbane, Queensland — Site status not reported
- Women and Children's Hospital-Adelaide, Adelaide, South Australia — Site status not reported
- The Royal Children's Hospital - Melbourne, Melbourne, Victoria — Site status not reported
- 3. Royal Melbourne Hospital, Parkville, Victoria — Site status not reported
- Perth Children's Hospital, Nedlands, Western Australia — Site status not reported
Overall recruitment does not imply availability at every site. Confirm eligibility and local recruitment with the study team.
Primary endpoints
- Stimulated C-peptide area under the curve during a two-hour mixed-meal test at 12 months.
The full picture
JAKPOT is the TrialNet companion to the baricitinib story: a registry-described phase-2, placebo-controlled test of whether more selective oral JAK-pathway drugs (abrocitinib and ritlecitinib) can preserve C-peptide with acceptable safety; no results have been posted.
Sources
- [1]JAK inhibitors to preserve C-peptide production in new-onset T1D · Trial registry · 2026-05-29 — No results posted when checked 16 September 2026. Active, not recruiting; estimated enrollment 78. The 2 September update moves estimated primary completion to 30 October 2026 and full completion to 30 October 2027.